Difference between revisions of "Tebentafusp (Kimmtrak)"
Jump to navigation
Jump to search
m (Jwarner moved page Tebentafusp (IMCgp100) to Tebentafusp (Kimmtrak): FDA approval) |
m |
||
Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Uveal melanoma]] | *[[Uveal melanoma]] | ||
− | + | ||
+ | ==History of changes in FDA indication== | ||
+ | *1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic [[uveal melanoma]]. ''(Based on IMCgp100-202)'' | ||
==Also known as== | ==Also known as== |
Revision as of 11:04, 17 June 2022
Mechanism of action
Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.
Diseases for which it is used
History of changes in FDA indication
- 1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Based on IMCgp100-202)
Also known as
- Code name: IMCgp100
- Generic name: tebentafusp-tebn
- Brand name: Kimmtrak